跳到正文
FDA 官方药品与生物制品信息·AI 评分26

FDA 仿制药监管科学研究优先事项与获批项目(含 FY 2027 GDUFA 优先事项)

Generic Drug Research Priorities & Projects

AI 导读

FDA 依据 GDUFA 每年与产业界和公众协商制定仿制药监管科学研究优先事项,并公布 FY 2013 至 FY 2027 各年度优先事项文件。页面同时列出历年 GDUFA 监管科学公开研讨会与会议,以及 FY 2013 至 FY 2024 获批的科研合同与资助项目清单。

正文 · 原文

Each year, FDA consults with industry and the public to develop a list of regulatory science initiatives on generic drugs in accordance with the Generic Drug User Fee Amendments (GDUFA). These priorities are discussed and developed in public meetings and workshops and result in several awarded projects each year.

Research Priorities

GDUFA Regulatory Science Initiatives Public Workshops & Meetings

Awarded Projects

GDUFA Implementation

来源:FDA 官方药品与生物制品信息 · fda.gov